Neptune Technologies (NEPT) Reports Positive Preclinical Results for Leading Drug Candidate CaPre
Neptune Technologies & Bioressources Inc. is a leading innovator of science-based and clinically proven novel products for the nutraceutical and pharmaceutical markets. The company’s subsidiary, Acasti Pharma Inc., focuses primarily on treatments for chronic cardiovascular conditions within the over-the-counter, medical food and prescription drug markets. Acasti yesterday announced preclinical results demonstrating that its leading drug candidate CaPre™ outperformed the currently marketed Lovaza® by increasing HS-Omega-3 Index®. Lovaza is the only FDA-approved prescription fish oil solely indicated for the treatment of severe hypertriglyceridemia, a case of high glycerides, which can also lead to pancreatitis. The HS-Omega-3 Index measures an emerging risk…